Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Large Increase in Short Interest

Windtree Therapeutics, Inc. (NASDAQ:WINT) saw a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 83,000 shares, a growth of 44.9% from the February 13th total of 57,300 shares. Based on an average daily trading volume, of 318,400 shares, the short-interest ratio is presently 0.3 days. Currently, 11.1% of the company’s stock are sold short.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “neutral” rating and issued a $350.00 target price on shares of Windtree Therapeutics in a research report on Wednesday, December 4th.

Windtree Therapeutics Stock Down 0.5 %

Shares of WINT stock opened at $2.05 on Monday. Windtree Therapeutics has a 12 month low of $1.78 and a 12 month high of $737.44. The company’s fifty day simple moving average is $6.99 and its 200-day simple moving average is $47.92. The firm has a market cap of $1.54 million, a PE ratio of -0.12 and a beta of 0.68.

Institutional Investors Weigh In On Windtree Therapeutics

A hedge fund recently bought a new stake in Windtree Therapeutics stock. Renaissance Technologies LLC bought a new position in shares of Windtree Therapeutics, Inc. (NASDAQ:WINT) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 119,266 shares of the company’s stock, valued at approximately $42,000. Renaissance Technologies LLC owned approximately 1.08% of Windtree Therapeutics as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 29.33% of the company’s stock.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.